Erratum: High-temperature-required protein A2 as a predictive marker for response to chemotherapy and prognosis in patients with high-grade serous ovarian cancers(British Journal of Cancer (2015) 112 (739-744) DOI: 10.1038/bjc.2015.1);High-temperature-required protein A2 as a predictive marker for response to chemotherapy and prognosis in patients with high-grade serous ovarian cancers

British Journal of Cancer

Volumn 112, Issue 4, 2015, Pages 739-744

  Miyamoto, M ^a   Takano, M ^a   Iwaya, K ^a   Shinomiya, N ^a   Goto, T ^a   Kato, M ^a   Suzuki, A ^a   Aoyama, T ^a   Hirata, J ^a   Nagaoka, I ^b   Tsuda, H ^a   Furuya, K ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE HOSPITAL   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

Author keywords

high grade serous adenocarcinoma; high temperature required protein A2 (HtrA2); ovarian cancer; platinum sensitivity

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; HIGH TEMPERATURE REQUIRED PROTEIN A2; PACLITAXEL; PLATINUM; TAXANE DERIVATIVE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; MITOCHONDRIAL PROTEIN; SERINE PROTEINASE; SERINE PROTEINASE OMI; TUMOR MARKER;

ADULT; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER TISSUE; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IC50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; OVARY ADENOCARCINOMA; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; RISK FACTOR; TISSUE MICROARRAY; TREATMENT RESPONSE; AGED; CYSTADENOCARCINOMA, SEROUS; DISEASE FREE SURVIVAL; METABOLISM; OVARIAN NEOPLASMS; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; TREATMENT OUTCOME; TUMOR CELL LINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CELL LINE, TUMOR; CYSTADENOCARCINOMA, SEROUS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; MITOCHONDRIAL PROTEINS; NEOPLASM GRADING; OVARIAN NEOPLASMS; PROGNOSIS; SERINE ENDOPEPTIDASES; TREATMENT OUTCOME;

EID: 84923569933     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2016.371     Document Type: Erratum

References (23)

1. Cannistra SA. (2004). Cancer of the ovary. N Engl J Med 351: 2519-2529
2. Chien J, Aletti G, Baldi A, Catalano V, Muretto P, Keeney GL, Kalli KR, Staub J, Ehrmann M, Cliby WA, Lee YK, Bible KC, Hartmann LC, Kaufmann SH, Shridhar V. (2006). Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity. J Clin Invest 116: 1994-2004
3. Chien J, Staub J, Hu SI, Erickson-Johnson MR, Couch FJ, Smith DI, Crowl RM, Kaufmann SH, Shridhar V. (2004). A candidate tumor suppressor HtrA1 is downregulated in ovarian cancer. Oncogene 23: 1636-1644
4. Clausen T, Southan C, Ehrmann M. (2002). The HtrA family of proteases: implications for protein composition and cell fate. Mol Cell 10: 443-455
5. Faccio L, Fusco C, Chen A, Martinotti S, Bonventre JV, Zervos AS. (2000). Characterization of a novel human serine protease that has extensive homology to bacterial heat shock endoprotease HtrA and is regulated by kidney ischemia. J Biol Chem 275: 2581-2588
6. Hu SI, Carozza M, Klein M, Nantermet P, Luk D, Crowl RM. (1998). Human HtrA, an evolutionarily conserved serine protease identified as a differentially expressed gene product in osteoarthritic cartilage. J Biol Chem 273: 34406-34412
7. Inagaki A, Nishizawa H, Ota S, Suzuki M, Inuzuka H, Miyamura H, Sekiya T, Kurahashi H, Udagawa Y. (2012). Upregulation of HtrA4 in the placentas of patients with severe pre-eclampsia. Placenta 33: 919-926
8. Izeradjene K, Douglas L, Delaney AB, Houghton JA. (2004). Casein kinase I attenuates tumor necrosis factor-related apoptosis-inducing ligandinduced apoptosis by regulating the recruitment of fas-associated death domain and procaspase-8 to the death-inducing signaling complex. Cancer Res 64: 8036-8044
9. Kaminskyy VO, Piskunova T, Zborovskaya IB, Tchevkina EM, Zhivotovsky B. (2012). Suppression of basal autophagy reduces lung cancer cell proliferation and enhances caspase-dependent and -independent apoptosis by stimulating ROS formation. Autophagy 8: 1032-1044
10. Kikuchi Y, Miyauchi M, Kizawa I, Oomori K, Katoh K. (1986). Establishment of a cisplatin-resistant human ovarian cancer cell line. J Natl Cancer Inst 77: 1181-1185
11. Lipinska B, Zylicz M, Georgopoulos C. (1990). The HtrA (DegP) protein, essential for Escherichia coli survival at high temperatures, is an endopeptidase. J Bacteriol 172: 1791-1797
12. Narkiewicz J, Klasa-Mazurkiewicz D, Zurawa-Janicka D, Skorko-Glonek J, Emerich J, Lipinska B. (2008). Changes in mRNA and protein levels of human HtrA1, HtrA2 and HtrA3 in ovarian cancer. Clin Biochem 41: 561-569
13. Nie GY, Hampton A, Li Y, Findlay JK, Salamonsen LA. (2003). Identification and cloning of two isoforms of human high-temperature requirement factor A3 (HtrA3), characterization of its genomic structure and comparison of its tissue distribution with HtrA1 and HtrA2. Biochem J 371: 39-48
14. Sasa H, Hisano A, Ishii K, Hirata J, Kikuchi Y, Nagata I, Sendoo A, Aida S, Tamai S, Sugita M. (1993). Establishment of a cisplatin-resistant human on\varian cancer cell line. Human Cell 6: 106-113
15. Shimada M, Kigawa J, Ohishi Y, Yasuda M, Suzuki M, Hiura M, Nishimura R, Tabata T, Sugiyama T, Kaku T. (2009). Clinicopathological characteristics of mucinous adenocarcinoma of the ovary. Gynecol Oncol 113: 331-334
16. Singh H, Li Y, Fuller PJ, Harrison C, Rao J, Stephens AN, Nie G. (2013). HtrA3 is downregulated in cancer cell lines and significantly reduced in primary serous and granulosa cell ovarian tumors. J Cancer 4(2): 152-164
17. Suzuki Y, Takahashi-Niki K, Akagi T, Hashikawa T, Takahashi R. (2004). Mitochondrial protease Omi/HtrA2 enhances caspase activation through multiple pathways. Cell Death Differ 11: 208-216
18. Takano M, Tsuda H, Sugiyama T. (2012). Clear cell carcinoma of the ovary: is there a role of histology-specific treatment?. J Exp Clin Cancer Res 31: 53
19. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. (2000). New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216
20. Wang CY, Lin YS, Su WC, Chen CL, Lin CF. (2009). Glycogen synthase kinase-3 and Omi/HtrA2 induce annexin A2 cleavage followed by cell cycle inhibition and apoptosis. Mol Biol Cell 20: 4153-4161
21. Yamamoto K, Kikuchi Y, Kudoh K, Nagata I. (2000). Modulation of cisplatin sensitivity by taxol in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. J Cancer Res Clin Oncol 126: 168-172
22. Yang X, Xing H, Gao Q, Chen G, Lu Y, Wang S, Ma D. (2005). Regulation of HtrA2 by X-linked inhibitor of apoptosis protein in chemoresistance in human ovarian cancer cells. Gynecol Oncol 97: 413-421
23. Zurawa-Janicka D, Jarzab M, Polit A, Skorko-Glonek J, Lesner A, Gitlin A, Gieldon A, Ciarkowski J, Glaza P, Lubomska A, Lipinska B. (2013). Temperature-induced changes of HtrA2(Omi) protease activity and structure. Cell Stress Chaperones 18: 35-51